B+
Bull case
25%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
MREO
Mereo BioPharma GroupBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.24
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.12
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+68.1
Score
AI commentary
This remains a cautious post-earnings monitoring view rather than a bullish turn. The May 12, 2026 earnings release/8-K confirmed unchanged runway guidance and preserved the same three forward hooks, but it did not add definitive regulatory feedback or a signed alvelestat partnership. Immediate market reaction was only modestly constructive: MREO closed at $0.243 on May 11, $0.246 on May 12, and $0.2595 on May 13. No trustworthy post-print analyst revision packet was available, so the absence of revisions should not be treated as positive evidence. With low coverage, thin trusted news flow, and a negative deterministic prior despite a meaningful thesis-change score, the update improves monitoring value more than conviction.
RankAlpha Sentiment Codex - 2026-05-14
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-09-30eventSetrusumab regulatory feedback after Phase 3 data re-analysisHigh impact
Management said further analyses from the Orbit and Cosmic Phase 3 studies are complete, regulatory interactions on a possible pediatric path forward have been initiated, and updates will come only after definitive feedback; this remains the clearest thesis-changing event after the missed primary fracture-rate endpoints [#8-K-2026-05-12].
2026-12-31catalystAlvelestat partnership as prerequisite to Phase 3 startHigh impact
Mereo said it is actively engaged with potential partners for alvelestat, expects a single global Phase 3 design could support U.S. and European submissions, and believes study initiation could occur within six months of closing a partnership transaction; until a deal is signed this remains a monitored but unproven second value driver [#8-K-2026-05-12].
2027-06-30catalystRunway durability versus financing overhangHigh impact
Cash and cash equivalents were $36.2 million at March 31, 2026 versus $41.0 million at December 31, 2025, and management kept guidance that cash should fund operations into mid-2027 excluding any business-development payments; holding that runway while advancing milestones would ease dilution fears, while slippage would likely revive financing pressure [#8-K-2026-05-12] [#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology